Nautilus Biotechnology Inc. (NAUT)
NAUT trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NAUT on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001808805 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DELAWARE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $10.5M cash; operating cash flow -$13.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 127,372,425 (2026-10-22); 126,305,122 a year earlier; 124,945,774 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-09-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $71K, sold $11.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $234K | -$15.6M | -$13.3M | $10.5M | No debt tags | Needs four quarters | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | $190K | -$14.5M | -$13.7M | $13.2M | No debt tags | Needs four quarters | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | Not filed | -$14.7M | -$13.1M | $14.6M | No debt tags | Needs four quarters | 10-Q 2026-04-28 |
| Q4 2025 2025-12-31 | Not filed | -$13.8M | -$12.4M | $12.4M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $0 | -$13.6M | -$11.0M | $23.9M | No debt tags | Needs four quarters | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | $0 | -$15.0M | -$13.3M | $34.5M | No debt tags | Needs four quarters | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | Not filed | -$16.6M | -$13.9M | $33.2M | No debt tags | Needs four quarters | 10-Q 2026-04-28 |
| Q4 2024 2024-12-31 | Not filed | -$17.6M | -$14.3M | $27.6M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-18 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report | 8-K | 2026-10-27 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 328 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.0% |
| 1 month | +13.2% |
| 3 months | +160.7% |
| Year to date | +19.0% |
| 1 year | +22.8% |
| From 52-week high | -41.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LAB | Standard BioTools Inc. | $0.6210 | -12.21% | $245.2M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| PACB | Pacific Biosciences of California Inc. | $1.84 | -6.12% | $575.8M |
| CTKB | Cytek Biosciences Inc. | $5.63 | -3.60% | $736.3M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier